ClinicalTrials.gg
RecruitingNCT04978571Updated Oct 21, 2026

Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)

An interventional study of percutaneous electrical nerve-field stimulation, PENFS and percutaneous electrical nerve-field stimulation, PENFS (sham device) in Post-Concussion Syndrome, COVID Long-Haul and COVID-19, sponsored by Children's Hospital of Orange County. Recruiting at 1 site in United States. Open to participants aged 11 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Children's Hospital of Orange County · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.
Updated Oct 21, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
11 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Post-Concussion Syndrome with a site in United States — 15 open to participants now, 20 under way, 1 of them phase 3. Post-Concussion Syndrome · United States.

Planned enrollment
9th of 61
125 · median 40
Started
2021
with 7 others
No phase
35 of 77
6 open now
Primary completion
2026-12
later than 6 of 19 live
Registered
56th of 77
by date
Lead sponsor
2 of 77
Children's Hospital of Orange County

Among the 77 studies in Post-Concussion Syndrome with a site in United States, this one is the 9th largest by planned enrollment of the 61 interventional ones that give a count, is one of 8 that started in 2021, is one of 35 with no phase, reaches primary completion later than 6 of the 19 other live ones, and was the 56th registered.

Post-Concussion Syndrome

140 studies on the registry are indexed under Post-Concussion Syndrome; 33 are open to participants now.

Browse Post-Concussion Syndrome studies →

Open to participants now

15 of the 77 studies in Post-Concussion Syndrome with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Post-Concussion Syndrome studies recruiting now, 3 (13%) set no upper age limit and 20 (83%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 11 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Post-Concussion Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to test the effect of Auricular Percutaneous Electrical Nerve Field Stimulation (a Neurostim device) on children with pain and Post Concussion symptoms.

An additional purpose of this study is to demonstrate that PENFS improves functioning in children with post Covid-19 symptoms.

Read the detailed description

The purpose of this study is to test the effect of Auricular Percutaneous Electrical Nerve Field Stimulation (a Neurostim device) on children with pain and Post Concussion symptoms. Patient will be offered a Neurostim device. This device is placed on the outer ear through tiny needles. Since this is a randomized trial, patients may receive an active (experiment) or nonactive (control) Neurostim device. However, the nonactive control Neurostim device group will be given the option to receive an active device after the initial study procedures. The experiment group may be in this study up to 8 weeks and the control group may be in this study up to 12 weeks. The control group will have 4 additional weeks due to the transition to an active device following the first 8 weeks. The device is worn weekly for 4 weeks. Each device is worn for 5 consecutive days for the full 24 hours. The participant will be able to easily take the device off on the 6th day. Study procedures include: Neurological testing- a balance test and computerized neurological standard testing, Cardiology testing- electrocardiogram for heart rate variability (heart electrical pulse test), a pupilometer (eye) test, and parent/child questionnaires. You may benefit from this research, but there is no guarantee that being in this study will help you.

Patients in the COVID arm will be offered 6 placements of Neurostim devices. This device is placed on the outer ear through tiny needles. Patients in this arm will not be randomized, all patients will receive active devices. This group will be in the study for up to 10 weeks. The device is worn weekly for 6 weeks. Each device is worn for 5 consecutive days for the full 24 hours. The patient will be able to remove the device on the 6th day. Study procedures include: Neurological testing called Cognigram to measure cognitive functioning and parent/child questionnaires. After 6 weeks of device placements, parent and child will complete a 1-week and 1-questionnaires. You may benefit from this research, but there is no guarantee that being in this study will help you.

03

Conditions studied

  • Post-Concussion Syndrome
  • COVID Long-Haul
  • COVID-19
04

Who can participate

Ages eligible
11 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Concussion:

Inclusion Criteria:

  • Clinical diagnosis of Post-Concussion Syndrome
  • Post-Concussion Symptoms for at least 3 months along with lack of other explanation for their symptoms
  • English and Spanish-speaking families

Exclusion Criteria:

  • Seizure disorders
  • Significant developmental delay
  • Infection or severe dermatological condition of ear
  • Bleeding disorders
  • Implanted electrical device

COVID:

Inclusion Criteria

  • Child is in between the ages 11-18
  • Child is present at CHOC Neurology clinic post covid-19 symptoms of more than 3 months duration along with lack of other explanation for their symptoms
  • English-speaking and Spanish-speaking families

You cannot participate in this study if you meet the following exclusion criteria:

  • Children with significant developmental delay, infection or severe dermatological condition of ear, bleeding disorders, or having any implanted electrical device will be excluded.
  • Are not able to attend Friday appointments for the Neurostim placements.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
125 participants (estimated)

Study arms

  • Experimental
    Active Neurostim Device

    Patients in this group will receive the active devices for the initial 4 study weeks.

    Device: percutaneous electrical nerve-field stimulation, PENFS

  • Sham comparator
    Sham Neurostim Device

    Patients in this group will receive the sham devices for the initial 4 study weeks. However, they will be offered the 4 active devices after.

    Device: percutaneous electrical nerve-field stimulation, PENFS (sham device)

  • Experimental
    COVID Active Neurostim Device

    Patients in this group will receive the active devices for the 6 study weeks.

    Device: percutaneous electrical nerve-field stimulation, PENFS (COVID active device)

Interventions

  • Devicepercutaneous electrical nerve-field stimulation, PENFS

    A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear

  • Devicepercutaneous electrical nerve-field stimulation, PENFS (sham device)

    A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear. The sham device will not deliver field stimulation to the ear.

  • Devicepercutaneous electrical nerve-field stimulation, PENFS (COVID active device)

    A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear

06

What researchers measure

Primary outcomes

  1. Immediate Post-Concussion Assessment

    With the Immediate Post-Concussion Assessment, percentiles indicate functioning assessment after a concussion. Having a higher score on this assessment implies having a worse outcome assessment.

    Time frame: 8 weeks

  2. Post-Concussion Symptom Scale

    Post Concussion Symptom Scale- a 22 item questionnaire, rated on a 0-6 scale. Having a higher score indicates having worse symptom assessment.

    Time frame: 8 weeks

  3. Balance Error Scoring Symptom

    Balance Error Scoring Symptom- a balance test conducted in person. Patient is asked to do a 3 poses on the floor and 3 poses standing on a foam and asked to stand still. The amount of errors will be counted for the times the patient moves. The higher the errors, means patient does not have a well-balance.

    Time frame: 8 weeks

  4. COGNIGRAM

    COGNIGRAM is a test prescribed by clinicians to measure cognitive function.

    Time frame: 10 weeks

Secondary outcomes

  1. Abdominal Pain Index

    4 item to rate abdominal pain. Higher score indicates having worse outcome.

    Time frame: 8 weeks

  2. Baxter Animated Retching Faces Nausea Scale

    rate on a 1-10 scale level of nausea. Higher score indicated feeling worse.

    Time frame: 8 weeks

  3. Children's Somatization inventory

    23 item to rate symptoms, higher score indicates worse symptoms

    Time frame: 8 weeks

  4. Functioning disability inventory

    15 item, asking on functioning, higher score indicated worse outcome.

    Time frame: 8 weeks

  5. Patient-Reported Outcomes Measurement Information System- Anxiety

    8 item questionnaire asking on anxiety level. Higher score indicates worse outcome.

    Time frame: 8 weeks

  6. Patient-Reported Outcomes Measurement Information System- Depression

    8 item asking on depression, higher score indicated worse outcome

    Time frame: 8 weeks

  7. Patient-Reported Outcomes Measurement Information System-Global health scales

    7-item asking on general health, lower score indicates worse outcome

    Time frame: 8 weeks

  8. Covid-19 questionnaire

    40-item asking Covid related symptoms and history.

    Time frame: 10 weeks

Other outcomes

  1. Orthostatic Vitals

    numerical number that determines blood pressure. Having a high blood pressure indicates worse outcome. Reading will be done by a provider.

    Time frame: 8 weeks

  2. Electrocardiography

    Heart rate measurement- a recording of electrical signal from the heart to check for heart conditions. Reading will be done by a provider.

    Time frame: 8 weeks

  3. Pupillometry

    Pupillometry: An eye assessment to measure pupil size and reactivity, reading will be done by a provider

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Dec 2026, 70 months after the start.

Of 54 non-industry interventional studies with no phase under Post-Concussion Syndrome, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 58. This study's planned 70 months is above that.

Counting every sponsor, half of 56 studies reached it within 40 months; a quarter within 23 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2021
First posted
Jul 27, 2021
StartActual
Feb 1, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: j•••@choc.org · •••8765→g•••@choc.org · •••8765. See the current contact
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Contact Study contact changed: j•••@choc.org · •••8765→g•••@choc.org · •••8765. See the current contact
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04978571
Lead sponsor
Children's Hospital of Orange County
Responsible party
Ashish Chogle (Principal Investigator, Children's Hospital of Orange County) — Principal investigator
First posted
Jul 27, 2021
Start date
Feb 1, 2021
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Pari Mokhtari
Contact
pari.mokhtari@choc.org
714-509-8765
Gabriela Velazquez
Contact
gabriela.velazquez@choc.org
714-509-8765

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion